Where does CSL Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), CSL Limited ranks #5,203 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does CSL Limited hold?

CSL Limited holds 66 US utility patents granted between 2015 and 2025, spanning 9 technology areas.

What is CSL Limited's Innovation Score?

CSL Limited has an Innovation Score of 37.9 out of 100 (top 42% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does CSL Limited focus on?

CSL Limited's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 58 patents, ranking #299 of 6,058 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is CSL Limited's patent grant rate increasing or decreasing?

CSL Limited's recent grant velocity is -44% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for CSL Limited's patents?

CSL Limited's patents average 14.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the CSL Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

CSL Limited

USPTO PatentsView assignee record - 66 granted patents across 9 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, CSL ranks #5,203 of 49,997 tracked US assignees by granted-patent volume, with 66 patents across 9 technology areas.

#5,203
of 49,997 US assignees by volume: Top 42%
by Innovation Score (37.9/100): 14.6
avg claims per patent: -44%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R5203 · Foreign Corporation #5,203 · 66 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 66 grants
UPPER-Q #5,203/49,997
PHOTO-FINISH Babyliss Faco SRL
CPC-NARROW A61P · 9 areas
INNOV-THIN 37.9/100
CLAIMS-RICH 14.6 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -44% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Babyliss Faco SRL (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How CSL’s 37.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 14.5 pts (38%) Velocity 4.0 pts (11%) Breadth 10.6 pts (28%) Claim depth 8.7 pts (23%)

Qualcomm Incorporated · highest

85
Angel Medical Systems · near

38
CSL · this assignee

38
cytena · near

38
Leaf Healthcare · near

38
Tyfone · near

38
3D Lighting… · lowest

7

What this shows CSL's Innovation Score is 37.9/100 (top 42% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for CSL?

Each dot is one of CSL’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). CSL’s own 14.6 claims/patent is at or below the 17.2 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

CSL vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where CSL's grants concentrate

CSL Limited is a focused PatentsView assignee: 9 CPC subclasses with 87.9% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2018 (10 grants) versus a trough of 2 in 2024. By volume, CSL sits between Babyliss Faco SRL and Flir Belgium Bvba.

CSL's three-year grant acceleration

From 2019–2021 to 2022–2024, CSL Limited moved from 20 to 12 grants (0.60x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Babyliss Faco SRL

66
Bal Seal Engineer…

66
Bridgeport Fittin…

66
Central Japan Rai…

66
Canon U S Life Sc…

66
Dionex Softron

66
Ecole Polytechniq…

66
Flir Belgium Bvba

66
CSL ◀

66

What this shows CSL holds 66 patents at rank #5,202, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near CSL

By rank, the assignees closest to #5,202 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in CSL's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for CSL, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), CSL ranks #299 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (38 here).

Leaf Healthcare, Inc. 38 Angel Medical Systems Inc. 38 cytena GmbH 38 Tyfone, Inc. 38

Similar claim depth

Nearest assignees by average claims per patent (14.6 here).

Astrium GMBH 14.6 avg Lumens Co., Ltd. 14.6 avg Global Unichip Corporation 14.6 avg Kyocera AVX Components (San Diego), Inc. 14.6 avg

CSL's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 42% higher than 58% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

CSL Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	9	13.6%
2016	8	12.1%
2017	5	7.6%
2018	10	15.2%
2019	9	13.6%
2020	6	9.1%
2021	5	7.6%
2022	7	10.6%
2023	3	4.5%
2024	2	3.0%
2025partial year	2	3.0%

Which technologies does CSL Limited patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 58

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 57

C07K - Peptides 56

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 14

C12Y - Enzymes 7

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 5

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 4

Y02A - Technologies FOR Adaptation TO Climate Change 4

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

CSL Limited's patent record in context - here's where to go next.

CSL Limited's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 87.9% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #5,203 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare CSL Limited against Babyliss Faco SRL, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 37.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.